PFI (MCA): Modeling the Transport of Pharmaceutical Agents Across the Placental Barrier

Information

  • NSF Award
  • 2321975
Owner
  • Award Id
    2321975
  • Award Effective Date
    9/1/2023 - 10 months ago
  • Award Expiration Date
    8/31/2026 - 2 years from now
  • Award Amount
    $ 350,000.00
  • Award Instrument
    Standard Grant

PFI (MCA): Modeling the Transport of Pharmaceutical Agents Across the Placental Barrier

The broader impact/commercial potential of this Partnerships for Innovation – Mid Career Advancement (PFI-MCA) project lies in an innovative approach and platform technology – integrating 3D cell culture, sensing, and imaging. This system will further enable understanding of physiological processes and can be personalized for each expecting mother using their stem cells, leading to higher accuracy in testing for the transport rate of specific compounds and setting safe exposure levels. The successful completion of this project will lead to an economical and physiologically relevant tool that accommodates testing of a larger number of compounds, facilitates high-throughput screening and rapid data collection, and thus ensures market potential for this technology.<br/><br/>The proposed project presents a paradigm shift from the approach currently used to study the transport of pharmaceutical drugs through the placental barrier and their effects on the developing placenta. This platform will replicate the physiological matrix mechanics, hemodynamics, and compound’s ability to permeate through the placental barrier, which will enable quantitative studies to be performed on a vast range of pharmaceuticals to understand their interactions, including transport through the vasculature, and translocation across the placental barrier to diffuse into the fetal blood stream. Furthermore, the system can ultimately be personalized for each expecting mother using their stem cells. This could lead to higher accuracy in testing the transport rate of certain compounds while reducing the cost and enabling real-time monitoring and rapid data collection. Collectively, the proposed technology enables the understanding of critical metabolic and inflammatory processes in the placenta, laying the foundation for its potential commercialization in the future.<br/><br/>This project is jointly funded by the Partnerships for Innovation program and the Established Program to Stimulate Competitive Research (EPSCoR).<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

  • Program Officer
    Debora Rodriguesderodrig@nsf.gov7032924767
  • Min Amd Letter Date
    8/22/2023 - 10 months ago
  • Max Amd Letter Date
    8/22/2023 - 10 months ago
  • ARRA Amount

Institutions

  • Name
    Iowa State University
  • City
    AMES
  • State
    IA
  • Country
    United States
  • Address
    1350 BEARDSHEAR HALL
  • Postal Code
    500112103
  • Phone Number
    5152945225

Investigators

  • First Name
    Nicole
  • Last Name
    Hashemi
  • Email Address
    nastaran@iastate.edu
  • Start Date
    8/22/2023 12:00:00 AM

Program Element

  • Text
    PFI-Partnrships for Innovation
  • Code
    1662
  • Text
    EPSCoR Co-Funding
  • Code
    9150

Program Reference

  • Text
    BIOMEDICAL ENG AND DIAGNOSTICS
  • Text
    EXP PROG TO STIM COMP RES
  • Code
    9150